Mammalian in vivo and in vitro cytogenetic assays: a report of the U.S. EPA's gene-tox program. 1981

R J Preston, and W Au, and M A Bender, and J G Brewen, and A V Carrano, and J A Heddle, and A F McFee, and S Wolff, and J S Wassom

This report presents an assessment made by the U.S. Environmental Protection Agency Gene-Tox Program's Work Group on mammalian cytogenetics of the clastogenic effects of chemicals in in vivo and in vitro mammalian cell assays. This assessment is based on information provided by the Environmental Mutagen Information Center, Oak Ridge National Laboratory, with the proviso that the experimental protocol used in these papers was adjudged to be acceptable by standards outlined by the Work Group. Some data were accepted as "qualitative only" because the protocol used was fairly close to that proposed as suitable. Using these criteria, 177 papers were selected for review. 6 assays were reviewed: bone marrow (32 papers, 31 chemicals), spermatogonial (10 papers, 10 chemicals), spermatocyte (25 papers, 25 chemicals), oocyte or early embryo (18 papers, 19 chemicals), in vitro cell culture (30 papers, 66 chemicals), and leukocyte (66 papers, 53 chemicals). Each assay was considered separately, and comparisons were then made between them for their similarities or differences in producing a positive or negative clastogenic effect of a particular chemical or chemical class. A large proportion of the available cytogenetic data was not suitable for inclusion in the final data base because of poor experimental design or unsatisfactory reporting of the information. It was not possible to recommend any one assay for determining potential clastogenicity because each had its own particular advantages and limitations and provided unique information. For demonstrating in vivo effects, the bone-marrow assay is probably the simplest and most economical. If only in vitro exposures were considered, leukocytes or cultured mammalian cell lines would be suitable. However, there are advantages to using leukocytes because they are a synchronous population, at least through their cell division, and because of the ready availability of human cells. In general, there was good agreement between clastogenicity and carcinogenicity.

UI MeSH Term Description Entries
D008297 Male Males
D009153 Mutagens Chemical agents that increase the rate of genetic mutation by interfering with the function of nucleic acids. A clastogen is a specific mutagen that causes breaks in chromosomes. Clastogen,Clastogens,Genotoxin,Genotoxins,Mutagen
D001853 Bone Marrow The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells. Marrow,Red Marrow,Yellow Marrow,Marrow, Bone,Marrow, Red,Marrow, Yellow
D002273 Carcinogens Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. Carcinogen,Oncogen,Oncogens,Tumor Initiator,Tumor Initiators,Tumor Promoter,Tumor Promoters,Initiator, Tumor,Initiators, Tumor,Promoter, Tumor,Promoters, Tumor
D002453 Cell Cycle The complex series of phenomena, occurring between the end of one CELL DIVISION and the end of the next, by which cellular material is duplicated and then divided between two daughter cells. The cell cycle includes INTERPHASE, which includes G0 PHASE; G1 PHASE; S PHASE; and G2 PHASE, and CELL DIVISION PHASE. Cell Division Cycle,Cell Cycles,Cell Division Cycles,Cycle, Cell,Cycle, Cell Division,Cycles, Cell,Cycles, Cell Division,Division Cycle, Cell,Division Cycles, Cell
D003584 Cytological Techniques Methods used to study CELLS. Cytologic Technics,Cytological Technic,Cytological Technics,Cytological Technique,Technic, Cytological,Technics, Cytological,Technique, Cytological,Techniques, Cytological,Cytologic Technic,Technic, Cytologic,Technics, Cytologic
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001711 Biotransformation The chemical alteration of an exogenous substance by or in a biological system. The alteration may inactivate the compound or it may result in the production of an active metabolite of an inactive parent compound. The alterations may be divided into METABOLIC DETOXICATION, PHASE I and METABOLIC DETOXICATION, PHASE II.
D013090 Spermatocytes Male germ cells derived from SPERMATOGONIA. The euploid primary spermatocytes undergo MEIOSIS and give rise to the haploid secondary spermatocytes which in turn give rise to SPERMATIDS. Spermiocytes,Spermatocyte,Spermiocyte

Related Publications

R J Preston, and W Au, and M A Bender, and J G Brewen, and A V Carrano, and J A Heddle, and A F McFee, and S Wolff, and J S Wassom
December 1983, Regulatory toxicology and pharmacology : RTP,
R J Preston, and W Au, and M A Bender, and J G Brewen, and A V Carrano, and J A Heddle, and A F McFee, and S Wolff, and J S Wassom
November 1982, Mutation research,
R J Preston, and W Au, and M A Bender, and J G Brewen, and A V Carrano, and J A Heddle, and A F McFee, and S Wolff, and J S Wassom
November 1982, Mutation research,
R J Preston, and W Au, and M A Bender, and J G Brewen, and A V Carrano, and J A Heddle, and A F McFee, and S Wolff, and J S Wassom
May 1982, Mutation research,
R J Preston, and W Au, and M A Bender, and J G Brewen, and A V Carrano, and J A Heddle, and A F McFee, and S Wolff, and J S Wassom
July 1990, Mutation research,
R J Preston, and W Au, and M A Bender, and J G Brewen, and A V Carrano, and J A Heddle, and A F McFee, and S Wolff, and J S Wassom
September 1986, Mutation research,
R J Preston, and W Au, and M A Bender, and J G Brewen, and A V Carrano, and J A Heddle, and A F McFee, and S Wolff, and J S Wassom
November 1982, Mutation research,
R J Preston, and W Au, and M A Bender, and J G Brewen, and A V Carrano, and J A Heddle, and A F McFee, and S Wolff, and J S Wassom
November 1981, Mutation research,
R J Preston, and W Au, and M A Bender, and J G Brewen, and A V Carrano, and J A Heddle, and A F McFee, and S Wolff, and J S Wassom
January 1984, Mutation research,
R J Preston, and W Au, and M A Bender, and J G Brewen, and A V Carrano, and J A Heddle, and A F McFee, and S Wolff, and J S Wassom
December 1983, Mutation research,
Copied contents to your clipboard!